Wednesday, January 12, 2011

Venus Remedies - Clinical data on its novel anibiotic formulation- Sulbactomax expected shortly

A positive outcome from the PhIII study which was expected to be completed by September 2010 has not reported data as yet. The data is important for Venus to get European approval for its novel antibiotic formulation - Sulbactomax
The drug is expected to contribute $30m in sales and a similar amount on the bottom line, which should lead to more than trebling of profits from current levels.

The stock is damn cheap at current levels, trading at 5x earnings.